A 23-year-old male suffering from severe aplastic anemia (SAA) weighing 60 kg was successfully treated by unrelated allo-CBSCT (cord blood stem cell transplantation). A six-loci HLA-identical umbilical cord blood (UCB) was infused after conditioning with low-dose cyclophosphamide ( 
The patient was admitted on 20 June 1998 because of pallor, vertigo and gum bleeding. He had no tenderness of the sternum, or enlargement of liver, spleen and lymph nodes. The peripheral blood was characterized by pancytopenia which developed progressively. The anemia was normocytic and normochromic with RBC 1.23 ϫ 10 12 /l, Hb 47 g/l. The lowest WBC was 1.6 ϫ 10 9 /l (N45%), BPC 16 ϫ 10 9 /l. Bone marrow smear showed failure of hematopoiesis and increased nonhematopoietic cells and fat cells. Hemolytic screening tests were negative for acidified-serum hemolysis test, sucrose lysis test and venom hemolysis test.
The patient received immunosuppressive agents before UCBT (umbilical cord blood transplantation): ALG (Pasteur Merieux, Lyon, France) 10 mg/kg/day intravenous infusion from the 1st-5th day; prednisolone 10 mg/kg/day for the first 5 days followed by gradually decreased dosage until the 30th day. Cyclosporin was given from the 31st day, 2 mg/kg/day for 2 months in combination with stanolol, GM-CSF and EPO, but there was no response. The patient needed persistent transfusions of platelets and/or red cells. The patient was entered in a search program for an HLA-matched BM but this failed and autologous back-up marrow was prepared before UCBT. The HLA-identical UCB was found in Guangzhou cord blood bank with the cell typing of A11,−; B75(15),B46; DRB1 * 1202,15. The ABO blood group of donor was group AB, whilst the recipient was group B.
UCB was collected after delivery and cryopreserved in 10% DMSO in a programmed cell freezer to avoid cell loss which might impair engraftment. Syphilis and viral tests including HIV, hepatitis B and C and CMV were performed on both the mother's blood and the cord blood. Tests for genetic diseases such as thalassemia were also performed. The cord blood was kept in liquid nitrogen below −192°C. Trypan blue test to determine the viable cell frequency, flow cytometry to count CD34 + cells and cell culture for CFU-GM were done immediately after the cells were thawed ( Table 1) .
The patient received a pretransplant regimen of both ALG 40 mg/kg/day ϫ 3 days and CTX 20 mg/kg/day ϫ 3 days. GVHD prophylaxis consisted of CsA 4 mg/kg/day (days 1-5) followed by regulated dosage according to blood CsA level and MTX 15 mg/m 2 (day 1) and 12 mg/m 2 (days 3, 6, 11). Prophylaxis of infections included acyclovir, fluconazole, ofloxacin and metronidazole. The CMV status of the patient was negative. The patient was given a combination of G-CSF 5 g/kg/day and EPO 6000 IU every other day from day 0 until recovery from aplasia. Two units of concentrated red cells and 2 ϫ 5 units of platelets were infused before recovery of hematopoiesis. The status of engraftment was verified by DNA amplification and Table 1 Cord blood data after thawing microsatellite DNA fingerprinting for the CSF1PO locus ( Figure 1 ). The DNA samples were extracted from bone marrow and/or peripheral white blood cells. The features of the consecutive samples of the recipient's peripheral blood from the start of the transplant are listed in Table 2 . The bone marrow aspirates showed severe aplasia of three series before transplant and gradual recovery of hematopoiesis for 17 months without obvious abnormalities in the bone marrow.
CsA had been used until the end of the 10th month when a skin rash on the left shoulder and neck appeared and localized erythroderma developed. The skin biopsy demonstrated a subcutaneous infiltration by lymphocytes. No management has been arranged for this mild cGVHD which has been persistent but has not progressed. No involvment was manifested in liver or gut. Seventeen months after transplant, the red blood cells of the recipient remain of host origin (blood group B). Table 2 Consecutive observations for recipient's peripheral blood 
Discussion
Hematopoietic stem cell transplantation has been employed as one of the most effective means for the therapy of severe aplastic anemia. 1 Umbilical cord blood has recently emerged as an alternative source of hematopoietic stem cells especially for those patients lacking an HLA-matched related donor. Cord blood can be collected and stored on a large scale, has no risk to donors, lower risk of GVHD and better ability to reconstitute hematopoiesis and immunity after transplant. UCB contains a significantly higher number of early and commited progenitor cells and is now widely used in patients with malignant and non-malignant hematological diseases. UCBT mainly remains applied to children because of the limited number of hematopoietic cells, raising the question of whether it can reconstitute adult patients. Gluckman 2 indicated that neutrophil recovery was 76% in patients receiving Ͻ3.7 ϫ 10 7 NC/kg in UCBT including some adult patients. Kai 3 reported six adults with leukemia receiving UCBT and all the patients had full chimerism. We report here a case of severe aplastic anemia successfully treated with UCB 1.89 ϫ 10 7 NC/kg. The hematopoietic cells from UCB have engrafted in the recipient and have persisted for 17 months.
A lower incidence of severe GVHD after unrelated UCBT reflects the immaturity of UCB immunoeffector cells which permit more mismatching in unrelated transplantation. Kurtzbergh et al 4 thought that more advantage could be taken of engrafting unrelated cells into recipients of fully HLA-matched UCB than of mismatched UCB. Our experience indicated that the best matched UCB should be chosen for successful engraftment. The patient was prepared with a conditioning regimen consisting of cyclophosphamide of total dosage 60 mg/kg, only 1/3 of the usual dose of 200 mg/kg 5 used as the conditioning regimen for BMT in the treatment of SAA, to decrease the risk of graft failure. Additionally, ALG was applied to suppress the recipient's immuno-rejection of UCB cells. A stable mixed chimera was formed and continues to appear in the DNA fingerprinting map. The patient reserved his original hematopoietic function owing to our non-ablative measurements. Thus there may be a donor-recipient tolerance after transplant in this case.
The patient demonstrated evidence of GVHD 10 months after transplantation which was only localized erythematous plaques and papules classified as localized cGVHD. 6 No therapy was needed for such a mild skin lesion which has gradually subsided. There was no evidence of GVHD in the gut or in the liver.
Brady et al 7 reported nine patients with severe combined immunodeficiency (SCID) who underwent successful allo-BMT from ABO-mismatched donors. Eight of the nine patients had only host red cells circulating at 6 to 84 months after transplantation, while one patient had only donor red cells at 48 months after transplantation. Brady indicated the milder conditioning regimens or T cell depletion may play a role in this different outcome. The inability to find circulating red cells of donor origin may be due to a failure of engrafted donor stem cells to differentiate along the erythroid lineage. Brdicka et al 8 followed up six patients after BMT and revealed that DNA analysis showed full engraftment in all six patients while red cells in some of them indicated persistence of recipient bone marrow activity. Lindstrom et al 9 reported a CML patient (blood group A) receiving a bone marrow graft from an HLAidentical blood group O donor. Twelve months after BMT, the red cells of the patient remained agglutinable with anti-A blood group agents. Characteristics of an O secretor were seen in the plasma 3-4 weeks before cGVHD. After treatment of cGVHD, this feature disappeared. The blood group A antigen produced by the recipient seems to be persisting. We report a similar phenomenon 17 months after UBC transplantation. It is clear that the donor stem cells have long been engrafted, while the circulating red cells of the recipient remain of recipient origin.
